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Abstract
About 25% of the patients with bronchiectasis are likely to develop a chronic colonization with Pseudomonas aeruginosa. A better
understanding of predictors of acquiring Pseudomonaswithin the patient population may facilitate future focused research. The aim
of this retrospective observational study was to investigate predicting factors for P. aeruginosa colonization in patients with
bronchiectasis. This was a single-center retrospective cohort study using a bronchiectasis database which consisted of 211 patients
with bronchiectasis. Data were collected for demographic details, etiology, spirometry, microbiology data, maintenance medication
use, exacerbation frequency, hospital admission rate, and FACED and Bronchiectasis Severity Index (BSI) score. Two hundred
eleven patients were identified from our bronchiectasis database. Overall, 25% of the patients (n = 53) had a chronic colonization
with P. aeruginosa. Seventeen patients (8%) died in a 5-year follow-up period of whom 7 (41%) had a chronic P. aeruginosa
colonization (p > 0.05). After multiple regression analysis, P. aeruginosa-positive patients were significantly associated with an
older age (> 55 years) (p = 0.004), the use of hypertonic saline (0.042), and inhalation antibiotics (< 0.001). Furthermore, the presence
of PCD (p < 0.001) and post-infectious etiology (p < 0.001) as underlying causes were significantly associated with P. aeruginosa
colonization.We observed that independent predictors forP. aeruginosa colonizationwere age > 55 years, hypertonic saline, and PCD,
and post-infectious etiology as underlying causes of bronchiectasis. Since prevention ofP. aeruginosa colonization is an important aim
in the treatment of bronchiectasis, more attention could be directed to these groups at risk for Pseudomonas colonization.
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Introduction
About 25% (range from 9 to 33%) of the patients with bron-
chiectasis are likely to develop a chronic colonization with
Pseudomonas aeruginosa [1–3]. The available evidence to
date suggests thatP. aeruginosa colonization in bronchiectasis
is associated with poorer outcome in terms of hospital admis-
sions, exacerbation frequency, and mortality [3–7]. However,
the independent patient characteristics for P. aeruginosa col-
onization are not well known. A better understanding of the
predictors of acquiring Pseudomonas within the patient pop-
ulation may facilitate future focused research and identify
patient subgroups which may benefit from intensive manage-
ment to prevent chronic colonization as P. aeruginosa.
The aim of this retrospective observational study was to
investigate predicting factors for P. aeruginosa colonization
in patients with bronchiectasis.
Methods
Design
This was a single-center retrospective cohort study using a
bronchiectasis database of the department of pulmonary med-
icine of the Erasmus University Medical Center, Rotterdam,
The Netherlands. Patients who visited the outpatient clinic
between January 2012 and December 2016 were included.
The study cohort consisted of 211 patients with bronchiecta-
sis. Eligible patients were at least 18 years old and had been
diagnosed with bronchiectasis according to the typical
* A. Pieters
a.pieters@etz.nl
1 Erasmus Medical Center, Rotterdam, The Netherlands
European Journal of Clinical Microbiology & Infectious Diseases
https://doi.org/10.1007/s10096-019-03675-z
findings of abnormal dilatation of the bronchi found on high
resolution CT scan together with a clinical syndrome of
cough, sputum production, and airway infection. Patients with
a confirmed diagnosis of cystic fibrosis by genotyping and/or
sweat testing were excluded. The study has been approved by
the medical ethical committee of the Erasmus MC Rotterdam.
Procedures
The majority of patients were seen every 3 months at the
outpatient clinic. During a visit, a standard spirometry (FVC,
FEV1, and FEV1/FVC) was performed and sputum samples
were collected. The database consisting of individual case
notes was reviewed for the collection of demographic details,
details on the diagnosis of bronchiectasis, assessment of co-
morbidities (chronic obstructive pulmonary disease (COPD),
asthma, cardiac comorbidities, neurologic disorders, diabetic
mellitus, and chronic renal impairment), smoking history, lung
function test results in the baseline and follow-up, microbiol-
ogy data, maintenance medication use, exacerbation frequen-
cy, hospital admission rate, and FACED and Bronchiectasis
Severity Index (BSI) scores [4, 5]. Underlying etiology had
been identified according to the methods described by Pasteur
et al. [1, 8].
Patient data sets were derived from the hospital visit data-
base until data capture point (December 2016) or death.
Sputum cultures
Sputum samples were regularly obtained during outpatient
clinic visits or during hospital admissions and processed ac-
cording to the American Society of Microbiology guidelines
[9]. We regarded a sputum sample as representative when
more than 25 polymorphonuclear leucocytes and less than
10 squamous cells per low-power field were identified by
Gram stain. We established breakpoints according to the
European Committee on Antimicrobial Susceptibility
Testing [10].
Spirometry
Spirometry was performed according to ERS/ATS standards
in all patients using a standard spirometer at routine clinical
visits. The best FEV1% predicted value recorded in each year
was used in the analysis.
Outcome
For the determination of the impact of chronic P. aeruginosa
colonization, patients with at least two P. aeruginosa-positive
cultures, 3 months apart over the course of 12 months, were
compared with patients without this definition of chronic
P. aeruginosa colonization. Group comparisons were
performed with the collected data as have been described in
the Procedures section.
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences (SPSS), version 21.0 (SPSS
Inc., Chicago, IL, USA). Continuous variables were presented
as a mean standard deviation (SD) for normal distribution or
median with interquartile range (25th–75th percentile) for
non-normal distribution.
The incidence of exacerbation and hospital admission is
summarized as a per-person per-year rate. Differences in ex-
acerbations between groups were analyzed with the use of
nominal parametric data using Student’s t test and a non-
parametric Kruskal-Wallis test. The chi-squared test (Fisher’s
exact test, when appropriate) was used to compare propor-
tions. All p values were nominal and two-sides and were not
adjusted for multiple comparisons. p values less than 0.05
were considered significant.
Chronic P. aeruginosa colonization was analyzed as an
indicator variable (a patient did have or did not have a chronic
P. aeruginosa colonization) to determine factors associated
with chronic P. aeruginosa colonization, fitting univariate
models with the use of logistic regression. We used multino-
mial logistic regression to more fully characterize the associ-
ations between selected baseline factors and chronic
P. aeruginosa colonization. All variables that were explored
in the univariate logistic regression were considered in the
multivariate model (all different variables). A conservative
significance threshold of 0.04 was used to determine the qual-
ification of data for entry into or deletion from the model. The
odds ratio (OR), 95% confidence interval, and p value were
computed for each of presenting predictors.
Results
Patient population
Two hundred eleven patients were identified from our bron-
chiectasis database between January 2012 and December
2016. The time-dependent variables were evaluated in 2016;
they were comparable with the other observational study years
(Table 1). The cohort analysis showed that 54% of the patients
were male (n = 113) and that the median age was 60 years. In
the majority of cases, the cause of bronchiectasis was attrib-
uted to idiopathic and post-infectious diseases, in 31% and
20% respectively. One hundred thirty patients (63%) had nev-
er smoked. Of the current or previous smokers, the pack-years
interquartile range varied between 7 and 31 with a median of
18.5. HRCT scan showed that the majority of cases (n = 94;
[45%]) had three or more lobes affected. The distribution of
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Table 1 Patient characteristics
Parameters Overall cohort
(n = 211)
Chronic P. aeruginosa colonization
(n = 53)
No chronic P. aeruginosa colonization
(n = 158)
p value#
Age (years) 60 (45–74) 67 (57–77) 58 (43–73) 0.237
Age > 55 years 158 (75%) 40 (74%) 92 (58%) 0.025
Male: female 113 (54%) 30 (57%) 83 (53%) 0.607
BMI m kg−2 23 (20–26) 24 (20–28) 23 (20–26) 0.765
FEV1 predicted at baseline 79 (63–96) 75 (58–93) 81 (65–97) 0.184
Comorbid condition
Cardiologic comorbidities 50 (24%) 11 (21%) 39 (25%) 0.546
Neurologic disorders 24 (11%) 6 (11%) 18 (12%) 0.977
Diabetic mellitus 19 (9%) 3 (6%) 16 (10%) 0.414*
Chronic renal impairment 22 (11%) 3 (6%) 19 (12%) 0.185
Smoker 0.032
Never 130 (63%) 39 (75%) 91 (58%)
Ever or current 78 (37%) 13 (25%) 65 (42%)
Smoking pack-years 18.5 (6.5–30.5) 26 (13–39) 15 (3–28)
Exacerbation frequency < 0.001
None exacerbations 58 (32%) 6 (12%) 52 (40%)
One exacerbation 51 (29%) 12 (26%) 39 (30%)
≥ Two exacerbations 70 (39%) 29 (62%) 41 (31%)
Hospital admissions < 0.001
None hospital admissions 140 (78%) 28 (60%) 112 (85%)
≥ One hospital admissions(s) 39 (22%) 19 (40%) 20 (15%)
Cause
Idiopathic 65 (31%) 12 (22%) 54 (34%) 0.117
Post-infectious 43 (20%) 18 (34%) 25 (16%) 0.005
Primary or secondary
immunodeficiency
39 (19%) 5 (9%) 34 (22%) 0.050
PCD 17 (8%) 10 (19%) 7 (4%) 0.002*
COPD 14 (7%) 2 (4%) 11 (7%) 0.524*
ABPA 10 (5%) 3 (6%) 7 (4%) 0.714*
Severe asthma 10 (5%) – 10 (6%) 0.069*
Aspiration/reflux 8 (4%) 2 (4%) 6 (4%) –
IBD 3 (1%) – 3 (2%) –
Yellow nail syndrome 1 (1%) 1 (2%) – –
Job syndrome 1 (1%) – 1 (1%) –
Radiology (HRCT scan)
One lobe affected 43 (20%) 7 (13%) 36 (23%) 0.134
Two lobes affected 74 (35%) 13(25%) 61 (39%) 0.063
≥ Three lobes affected 94 (45%) 33 (62%) 61 (39%) 0.003
Pathogens (other than P. aeruginosa)
Staphylococcus aureus 26 (22%) 6 (15%) 20 (25%) 0.210
Haemophilus influenzae 11 (9%) 5 (13%) 6 (8%) 0.503*
Aspergillus fumigatus 23 (19%) 10 (25%) 13 (16%) 0.251
NTM 6 (5%) 3 (4%) 3 (8%) 0.399*
Stenotrophomonas maltophilia 9 (8%) 4 (10%) 5 (6%) 0.479*
Medications
Hypertonic saline - inhalation 85 (48%) 30 (64%) 55 (42%) 0.009
Inhalation antibiotics 31 (15%) 20 (42%) 11 (8%) < 0.001
Inhaled corticosteroids 19 (11%) 8 (17%) 11 (8%) 0.105*
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the severity score according to the FACED scale was 48%
(n = 99) mild, 32% (n = 67) moderate, and 20% (n = 41) se-
vere, and according to the BSI was 40% (n = 82) mild, 24%
(n = 50) was moderate, and 36% (n = 75) was severe.
The median (± interquartile range) follow-up period from
2012 was 47 months (± 13); 17 patients (8%) died in a 5-year
follow-up period of whom 7 (41%) had a chronic
P. aeruginosa colonization (p > 0.05).
Overall, 25% of the patients (n = 53) had a chronic coloni-
zation with P. aeruginosa.
With a univariate analysis, we analyzed difference in pro-
portions between P. aeruginosa-positive and P. aeruginosa-
negative patients, using all available baseline variables in the
whole cohort, showed in Table 1. Patients with P. aeruginosa
colonization had significantly more lobes affected on HRCT
scan compared with P. aeruginosa-negative patients (p =
0.003). The etiology seems to be different, with significantly
more frequent primary ciliary dyskinesia (PCD) (p = 0.002)
and post-infectious etiology (p = 0.005) as underlying causes
of bronchiectasis compared with patients without
P. aeruginosa colonization. Furthermore, an older age (>
55 years) was associated with P. aeruginosa colonization
(p = 0.025). Other significant differences between
P. aeruginosa colonizat ion and patients without
P. aeruginosa colonization were a higher rate of smoking sta-
tus (p = 0.032), a more frequent use of maintenance therapy
with macrolides (p = 0.001), and a worse outcome in the clin-
ical scoring systems according to the FACED scale
(p < 0.0001) and BSI scale (p < 0.0001). Subsequently, pa-
tients with P. aeruginosa colonization had a significantly
increased exacerbation frequency (p < 0.001) and an increased
number of hospital admissions (p < 0.001).
In multiple regression analysis, variables that were positive
after univariate analysis were used as predictors for
P. aeruginosa colonization. In the Pseudomonas colonization
group, exacerbation frequency and hospital admissions,
shown to be positive after the univariate analysis, were not
taken into account because we considered it the consequence
and not the cause of Pseudomonas colonization. Factors that
were independently associated with the presence of
P. aeruginosa colonization, on the basis of the multiple regres-
sion model, are shown in Table 2. P. aeruginosa-positive pa-
tients were significantly associated with an older age (>
55 years) (p = 0.004), the use of hypertonic saline (0.042),
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97 (54%) 68 (50%) 29 (62%) 0.229
Macrolides maintenance 136 (65%) 44 (83%) 92 (58%) 0.001
FACED scale < 0.0001
Mild 99 (48%) 8 (15%) 91 (59%)
Moderate 67 (32%) 23 (43%) 44 (29%)
Severe 41 (20%) 22 (42%) 19 (12%)
BSI scale < 0.0001
Mild 82 (40%) 3 (6%) 79 (51%)
Moderate 50 (24%) 9 (17%) 41 (27%)
Severe 75 (36%) 41 (77%) 34 (22%)
Data are presented as number of patients, unless otherwise stated
Data are displayed as median with 25th and 75th percentile in parentheses
COPD, chronic obstructive pulmonary disease; ABPA, allergic bronchopulmonary aspergillosis; PCD, primary ciliary dyskinesia; IBD, inflammatory
bowel disease; NTM, non-tuberculous mycobacteria
# Pa colonization versus others, analyzed with Mann-Whitney U test for continuous variables and a chi-square test for categorical variables
*Fisher’s test
Table 2 Factors associated with Pseudomonas aeruginosa colonization
(in the multivariate model)
Parameters Multivariable analysis
OR (95% C.I.) p value
Age > 55 years 0.150 (0.042–0.540) 0.004
HRCT (> 3 lobes affected) 0.516 (0.188–1.418) 0.199
PCD 0.040 (0.007–0.288) < 0.001
Post-infectious cause 0.048 (0.013–0.186) < 0.001
Macrolide maintenance 0.950 (0.321–2.901) 0.950
Hypertonic saline inhalation 0.309 (0.100–0.959) 0.042
Inhalation antibiotics 0.059 (0.016–0.220) < 0.001
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of PCD (p < 0.001) and post-infectious etiology (p < 0.001) as
underlying causes was significantly associated with
P. aeruginosa colonization.
Discussion
In our observational study of patients with bronchiectasis, we
identified patient characteristics which were associated with
the presence of persistent P. aeruginosa colonization. Patient
characteristics predicting for P. aeruginosa colonization were
older age, use of inhalation antibiotics and hypertonic saline,
and PCD and post-infectious etiology as underlying causes of
bronchiectasis.
Pseudomonas aeruginosa is an important pathogen in
bronchiectasis and functions as a marker for disease severity.
In our study, 25% of the patients had a chronic colonization
with P. aeruginosa. The average prevalence of P. aeruginosa
colonization in a recently published European survey was
15% [7]. In other studies, prevalence ranged from 9 to 33%
[1, 3]. In a subpopulation of our study, a remarkable high
prevalence of P. aeruginosa infection was present in patients
with PCD (58%) and in post-infectious (42%) causes of bron-
chiectasis. A comparable high rate of P. aeruginosa coloniza-
tion in PCD was reported in a prevalence study performed by
Shah et al. [11]. They found a prevalence of P. aeruginosa
colonization in 44% of PCD patients compared with 22% in
an adult bronchiectasis cohort. A recent study in patients with
PCD showed a prevalence of Pseudomonas colonization in
27.6% of the patient population [12]. Other predicting factors
for Pseudomonas colonization were the use of inhalation an-
tibiotics, which was not a surprise since inhalation antibiotics
were solely given to patients with Pseudomonas colonization.
The use of hypertonic saline also had been associated with
Pseudomonas colonization, which has not been described be-
fore. It is hard to determine whether the use of hypertonic
saline is a cause or consequence of Pseudomonas coloniza-
tion. In other studies, a significant association between worse
radiological imaging and P. aeruginosa colonization has been
reported [3–5, 13, 14]. However, we could not show this ob-
servation in our study. Another study also described a low
FEV1% predicted value and the presence of polymicrobial
colonization as independent predictors of P. aeruginosa colo-
nization [6].
In the study performed by Araujo et al., the presence of
P. aeruginosa colonization in patients with bronchiectasis
was associated with a worse quality of life and with an in-
crease in exacerbation frequency and hospital admissions [7].
They also showed that patients with frequent exacerbations,
who were colonized with P. aeruginosa, had an increased risk
of mortality. Finch et al. also showed in a review that
P. aeruginosa colonization was associated with a significant
increase in mortality risk [3]. However, we observed that there
was no relation between P. aeruginosa colonization and in-
creased mortality risk. This might be attributed to the smaller
sample size of our study. In total, 17 patients (8%) with bron-
chiectasis died in a 5-year observational period, of which 7
were colonized with P. aeruginosa. This percentage of mor-
tality is much lower than the 20.5% in a 5-year follow-up as
described by Goeminne et al. [15]. This could be explained by
the presence of a low percentage of COPD patients (7%) in
our population, since Goeminne et al. showed that patients
with COPD patients with bronchiectasis had a significant
higher mortality rate [15]. Furthermore, Araujo et al. showed
that one of the risk factors for mortality was the number of
exacerbations [7]. In our study, there were a high percentage
of patients receiving long-term macrolide treatment (65%) to
prevent exacerbations compared with the Goeminne study
with a macrolide treatment percentage of 40% [15]. Other
recent studies do not describe the percentage of macrolide
treatment, which in our opinion is important to mention
concerning the impact on frequency of exacerbations and
prognosis [6, 7, 15].
This study included several important limitations. First,
because it is a retrospective study, there is a risk of bias.
Second, since this was a single-center study, we included
a relatively small number of patients. Third, we defined
Pseudomonas co lon i z a t i on when a t l e a s t two
P. aeruginosa-positive cultures were present which were
3 months apart over the course of 12 months. There is a
lack of international criteria for defining Pseudomonas
colonization in bronchiectasis. In cystic fibrosis (CF),
the European consensus def in i t ion for chronic
Pseudomonas infection is the presence of at least three
positive cultures over ≥ 6 months with at least a 1-
month interval between the samples [16]. The Leeds
criteria for chronic Pseudomonas infection in CF refer to
patients in whom sputum cultures were positive for
Pseudomonas in > 50% of the samples during 12 months
[17]. Our experience is that it is more difficult to culture
Pseudomonas in bronchiectasis patients than in patients
with cystic fibrosis. Therefore, we used a more practical
definition; since in clinical practice, sputum cultures were
not always available.
To conclude, we observed that independent predictors for
P. aeruginosa colonization were age > 55 years, the use of
hypertonic saline, and PCD and post-infectious etiology as
underlying causes of bronchiectasis. Since prevention of
P. aeruginosa colonization is an important aim in the treat-
ment of bronchiectasis, more attention could be directed to
these groups at risk for Pseudomonas colonization.
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